Novo Nordisk

Ozempic (semaglutide)
#Cardiovascular disease #GLP-1 #Novo Nordisk #University College London

Semaglutide protects heart beyond weight loss benefits

Anti-obesity medication semaglutide may help to prevent heart attacks and other major cardiac events regardless of how much weight people lose while taking the drug, says a new study led by University College London (UCL).  The finding, the researchers say, suggests there are multiple ways the drug… Read More

#News #Trending News

Novo Nordisk head office
#Liver disease #Mergers and acquisitions #Metabolic diseases #Novo Nordisk

Akero Therapeutics acquired by Novo Nordisk for $5.2B

Akero Therapeutics, a clinical-stage company focused on serious metabolic diseases, has entered into a definitive agreement to be acquired by Novo Nordisk for up to $5.2 billion in cash. The acquisition was announced as Novo Nordisk revealed it is closing its cell therapy division, with a loss of 250 employees… Read More

#Business & Investment #News

RNA
#Cardiometabolic diseases #Collaboration #Novo Nordisk #Obesity #Replicate Bioscience #srRNA

Novo and Replicate partner on srRNA therapies for obesity

Novo Nordisk and Replicate Bioscience have announced a multi-year research collaboration that will combine Novo’s drug development expertise with Replicate’s srRNA platform to develop new therapeutic candidates for cardiometabolic diseases.  Under the terms of the agreement, Novo Nordisk will receive a defined exclusive, worldwide license to use Replicate’s srRNA platform… Read More

#Business & Investment #News

Human liver
#FDA #Fibrosis #GLP-1 #Liver disease #Novo Nordisk

Wegovy granted accelerated approval in the US for liver disease

The US Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide 2.4mg) as a treatment for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH).  The approval is in adults with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), in combination with a reduced calorie diet… Read More

#News #Regulatory #Trending News

#Cardiometabolic diseases #Collaboration #GPCRs #Novo Nordisk #Obesity

Novo Nordisk and Deep Apple announce collaboration

Novo Nordisk and Deep Apple Therapeutics have announced a research collaboration and exclusive worldwide license agreement to discover and develop oral small molecule therapeutics.  The new drugs will be directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.  Under the terms of the agreement, Deep Apple will… Read More

#Business & Investment #News

Heart monitor
#Cardiovascular disease #Chronic kidney disease (CKD) #Diabetes #GLP-1 #Novo Nordisk #Weight loss

Oral semaglutide reduces risk of cardiovascular events

The results of the SOUL cardiovascular outcomes trial have demonstrated that Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).   The new data were featured during a late-breaking clinical… Read More

#News

Novo Nordisk head office
#Association of the British Pharmaceutical Industry #Novo Nordisk

Novo Nordisk strengthens compliance and rejoins ABPI

Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ABPI) for serious breaches of the Code of Practice has come to an end.  The company’s return to full membership of the ABPI follows extensive audits of Novo Nordisk’s compliance procedures and governance by the Prescription Medicines Code… Read More

#Business & Investment #News #Regulatory

Magnifying glass
#Big pharma #Novo Nordisk #Pharmaceuticals #University of Bath

Critics say pharma giant has “deep cultural issues”

The UK’s Channel 4’s Dispatches: Skinny Jab Scandal investigational documentary has highlighted significant concerns about pharmaceutical giant Novo Nordisk’s promotional practices. Here, DDW outlines the case and provides comment from a Novo Nordisk spokesperson. The documentary featured expert insights from Dr Piotr Ozieranski and Dr Emily Rickard of the University… Read More

#Business & Investment #News

#GLP-1 #Market reporting #Novo Nordisk #Obesity #Scandinavia #Weight loss

What effect have weight loss drugs had on the Scandinavian economy?

In less than a decade GLP-1 receptor agonists have transformed the treatment of obesity and made Novo Nordisk Europe’s most valuable company. Diana Spencer explores the current impact and potential future for these drugs. Originally designed in Scandinavia as a maintenance therapy for type 2 diabetes, GLP-1 receptor agonists are… Read More

#Exclusive Content #Market Reports #Trends & Analysis

#Biotechnology #Cardiometabolic diseases #Diabetes #Funding #Novo Nordisk #Pioneer Group

UK biotech Golden Ticket programme open for applications

Pioneer Group has teamed up with global healthcare company Novo Nordisk to launch a ‘Golden Ticket’ programme designed to help accelerate innovations in cardiometabolic health. The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines in cardiometabolic diseases, rare blood and rare… Read More

#Business & Investment #News

#Cardiometabolic diseases #NanoVation Therapeutics #Novo Nordisk #Partnership #Rare disease

Novo Nordisk and NanoVation enter multi-target partnership

Novo Nordisk and NanoVation Therapeutics have announced a multi-year partnership to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The partnership will combine NanoVation Therapeutics’ long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery to cells outside of the liver with Novo Nordisk’s expertise in cardiometabolic and… Read More

#Business & Investment #News

Dorte Gram
#Fundraising #GLP-1 #Novo Nordisk #Obesity #Pila Pharma #Weight loss

Scientist who discovered Ozempic to study new obesity drug

Dorte Gram, founder of Pila Pharma and a former Novo Nordisk researcher who identified the molecule that became semaglutide, the active ingredient in Ozempic and Wegovy, has raised 10 million SEK ($980,320) for a novel obesity-related study. The money will allow the company to study drug… Read More

#News

Heart monitor
#Cardiovascular disease #Heart attack #MHRA #Novo Nordisk #Obesity #Weight loss

MHRA approves semaglutide to reduce risk of cardiovascular events

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new indication for semaglutide (Wegovy) to reduce the risk of overweight and obese adults suffering from heart attacks or stroke. The GLP-1 receptor agonist is already approved for use in the treatment of obesity and for weight management,… Read More

#News #Regulatory

Jigsaw puzzle of the brain
#Alzheimer's #Dementia #Diabetes #GLP-1 #Novo Nordisk #Phase II trial #Weight loss

GLP-1 receptor agonist slows Alzheimer’s cognitive decline

In new revelations about glucagon-like peptide-1 (GLP-1) drugs like Ozempic, a study has demonstrated the therapies could protect against dementia. In a Phase IIb trial, Novo Nordisk’s GLP-1 receptor agonist liraglutide appears to reduce shrinking in the parts of the brain that control memory, learning, language… Read More

#News #Trending News

Woman with a nose bleed
#Bispecific Antibodies #Events #Haemophilia #Novo Nordisk #Phase III trial

Bispecific antibody successfully reduced bleeds in haemophilia A

Novo Nordisk has announced results from the Phase III FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. The data… Read More

#News